Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer
John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.
EP: 1.Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer
EP: 2.Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer
EP: 3.Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer
EP: 4.Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer
EP: 5.Dr. Hanna on Approaching Biomarker Testing in Lung Cancer
EP: 6.Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer
EP: 7.Dr. Boyle on Approaching Biomarker Testing in Lung Cancer
EP: 8.New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C
John Longshore, PhD, FACMG, director, Molecular Pathology, Carolinas Pathology Group, Atrium Health, discusses key molecular markers in metastatic lung cancer.
The National Comprehensive Cancer Network guidelines recommend broad molecular testing. Genes that could harbor potentially actionable mutations and should be tested include EGFR, ALK, ROS1, BRAF, NTRK, HER2, MET exon 14 skipping, RET, and KRAS G12C. Additionally, tumor mutational burden should be profiled, says Longshore.
Despite the wealth of actionable targets in the metastatic setting, EGFR mutations are the only indicated molecular marker for early-stage disease based on the data from the phase 3 ADAURA trial, concludes Longshore.
